Valuation: Exact Sciences Corporation

Market Cap 20.03B 17.38B 16.27B 14.89B 28.1B 1,908B 28.47B 190B 74.71B 953B 75.19B 73.56B 3,172B P/E 2024
-10.1x
P/E 2025 -92.2x
Enterprise Value 21.6B 18.74B 17.55B 16.05B 30.31B 2,057B 30.7B 205B 80.57B 1,028B 81.09B 79.32B 3,421B EV / Sales 2024
4.4x
EV / Sales 2025 6.42x
Free-Float
98.24%
Yield 2024 *
-
Yield 2025 -
1 day+0.95%
6 months+2.19%
Current year+3.30%
Current year 101.51
Extreme 101.51
104.98
1 year 38.81
Extreme 38.8118
104.98
3 years 38.81
Extreme 38.8118
104.98
5 years 29.27
Extreme 29.27
108.99
10 years 13.05
Extreme 13.05
159.54
Date Insider Type Main position Quantity % Market Cap.
23/03/26 Free

Head of Human Resources

329,891 0.1728%
23/03/26 Issuer sale

General Counsel

93,932 0.0492%
27/02/26 Fiscal year

Chief Executive Officer

168,201 0.0882%
Change 5-day change 1-year change 3-year change Capi.($)
+0.95%-.--%+121.52%+23.03% 20.03B
-3.54%-2.03%+102.65%+253.58% 3.93B
-0.16%-23.08%+91.84%+85.50% 3.71B
-0.15%+19.48%+247.48%+321.48% 2.35B
-3.50%+1.96%-28.65%-36.92% 2.24B
+39.06%+30.38%+137.02%-13.26% 1.94B
-0.63%+10.83%+5.49% - 1.23B
-3.04%-8.07%+204.91%-43.69% 946M
+2.32%+12.77%-2.38%+13.44% 898M
+0.56%+2.46%-38.71%-11.26% 513M
Average +3.23%+1.80%+84.12%+65.77% 3.78B
Weighted average by Cap. +1.90%+0.80%+109.56%+65.31%

Financials

2024 2025
Net sales 2.76B 2.39B 2.24B 2.05B 3.87B 263B 3.92B 26.23B 10.29B 131B 10.36B 10.13B 437B 3.25B 2.82B 2.64B 2.41B 4.56B 309B 4.62B 30.87B 12.11B 155B 12.19B 11.93B 514B
Net income -1.03B -893M -836M -765M -1.44B -98.01B -1.46B -9.78B -3.84B -48.97B -3.86B -3.78B -163B -208M -180M -169M -155M -292M -19.81B -296M -1.98B -776M -9.9B -781M -764M -32.94B
Net Debt 1.74B 1.51B 1.41B 1.29B 2.44B 166B 2.47B 16.52B 6.48B 82.71B 6.52B 6.38B 275B 1.57B 1.36B 1.28B 1.17B 2.2B 150B 2.23B 14.93B 5.86B 74.73B 5.9B 5.77B 249B
Logo Exact Sciences Corporation
Exact Sciences Corporation is a provider of cancer screening and diagnostic tests. It offers a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. Its portfolio includes brands such as Cologuard and Oncotype DX, along with solutions like Cancerguard for blood-based analysis of molecular information across multiple cancers and Oncodetect for molecular residual disease and recurrence monitoring. Its flagship screening products, the Cologuard and Cologuard Plus tests, are patient-friendly, non-invasive, stool-based DNA (sDNA) screening tests that utilize a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Its Cancerguard test is designed to detect multiple cancers in their earliest stages from a single blood draw. It offers predefined genetic tests for all clinically relevant genes, and whole genome (PGnome) sequencing tests.
Employees
7,150
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
AAA
  1. Stock Market
  2. Stocks
  3. EXAS Stock